KEY EUROPEAN PATENT GRANTED FOR USE OF MESOBLAST'S MESENCHYMAL PRECURSOR CELLS IN CARDIAC AND VASCULAR CONDITIONS
Regenerative medicine company Mesoblast Limited announced that it has been granted a key patent by the European Patent Office covering its proprietary adult Mesenchymal Precursor Cells (MPCs) for use in the treatment of cardiac and vascular conditions. European patent number EP1613335, entitled ‘Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation’, provides Mesoblast with exclusive commercial rights in Europe initially through to 29 March 2024, with potential for extension based on duration of clinical development. MPC can be effective in treatment of cardiovascular disorders because of modulating blood vessel formation and tissue reparation. Company has been granted with patent for USe of MPC in heart failure treatment. Company has begun phase 2 and 3 clinical trials in Europe and USA.